Drugs / Suptavumab
Suptavumab
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02828397 | Apr → Sep 2016 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02121080 | May 2014 → Feb 2015 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT02325791 | Jul 2015 → Jul 2017 | respiratory syncytial virus infectious disease | Regeneron Pharmaceuticals | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2017-08-14 | Regeneron Pharmaceuticals | Results Regeneron to Discontinue Development of Suptavumab for Respiratory Syncytial Virus regeneron.com ↗
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that a Phase 3 study evaluating suptavumab (REGN2222), an antibody to respiratory syncytial virus (RSV), did not meet its primary endpoint of preventing medically-attended RSV infections in infants. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-08-14 | Regeneron Pharmaceuticals | Regeneron to Discontinue Development of Suptavumab for Respiratory Syncytial Virus regeneron.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Suptavumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02325791 ↗ |
| Known as | REGN2222 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02121080 ↗ |
| Known as | SAR438584 | “REGN2222(SAR438584)” NCT02121080 ↗ |
| Action | Inhibit | “bind and block a conserved epitope on RSV A and B subtypes” PMID 32897368 ↗ Dec 2021 |
| Modality | Monoclonal antibody | “suptavumab, a human monoclonal antibody that can bind and block a conserved epitope on RSV A and B subtypes” PMID 32897368 ↗ Dec 2021 |
| Route | Intramuscular | “Participants received single dose of suptavumab 30 milligram per kilogram (mg/kg) intramuscularly (IM) on Day 1.” NCT02325791 ↗ |